Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press110510.17650/1726-9776-2008-4-2-62-67DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыDocetaxel (Tautax) in the treatment of hormone-refractory prostate cancerТаутакс (доцетаксел) в лечении гормонорефрактерного рака предстательной железыRusakovI. G.РусаковИ. Г.
Russian Federation
BuharkinB. V.БухаркинБ. В.
Russian Federation

Moscow

Москва

AtaevA. M.АтаевА. М.
Russian Federation

Moscow

Москва

VereshaginG. V.ВерещагинГ. В.
Russian Federation
Moscow research oncologic center named after. P.A. GercenМНИОИ им. П.А. Герцена РосздраваRussian oncologic center named after N.N. BlohinРОНЦ им. Н.Н. Блохина РАМН300620084262671502202015022020https://oncourology.abvpress.ru/oncur/article/view/1105

Purpose. Evaluate efficacy and portability of the combination of the drugs Tautax (docetaxel) with a dose of 75mg/m2 1 time per 21 days and prednisolone — 10 mg per 24 h in hormone-refractory prostate cancer (HRPC) patients. Methods. Patients with verified HRPC were included in the study. Patients without being performed orchofuniculectomy were given LHRH analogues during the entire study. The treatment scheme was: tautax 75 mg/m2 1 time per 21 days as 1,5 h infusion + prednisolone — 10 mg per 24 h per os. Dexamethasone 8 mg was introduced intramuscularly as a premedication before tautax infusion prior to 12, 6 and 1 h. Patients with the revealed bone metastases were given zoledronic acid 4 mg 1 time per 28 days. The therapy was has been being performed for 6 months or till disease progression revelation. In case of regression or stabilization of the disease, up to 10 chemotherapy courses were performed. Results. 29 HRPC patients are examined. 178 chemotherapy courses are performed. Partial regression is noted in 8 (28%) patients, stabilization — in 9 (31%), progression - in 8 (28%) patients. PSA level decrease >50% has been observed in 19 (65,5%) patients. Improvement of the life quality was reached in 11 (38%) patients. The decrease in hyperfixation of radiopharmaceutical by osteoscintigraphy ocurred in 14 (48%) patients. Conclusion. Combination of Tautax and prednisolone is an effective treatment regimen of the HRPC patients.

.

1. Bamias A. et al. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331–43.Bamias A. et al. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331–43.2. Чиссов В.И. Онкологическая заболеваемость и смертность. М.; 2008.Чиссов В.И. Онкологическая заболеваемость и смертность. М.; 2008.3. Гарин А.М. 2-я линия эндокринной терапии и химиотерапия генерализованного рака предстательной железы. Материалы Европейской школы онкологов. ГУ РОНЦ им. Н.Н. Блохина. М.; 1997.Гарин А.М. 2-я линия эндокринной терапии и химиотерапия генерализованного рака предстательной железы. Материалы Европейской школы онкологов. ГУ РОНЦ им. Н.Н. Блохина. М.; 1997.4. Eisenberger M.A., Simon R., O'Dwyer P.J. et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827–41.Eisenberger M.A., Simon R., O'Dwyer P.J. et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827–41.5. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. Cancer 1993;71:1098–109.Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. Cancer 1993;71:1098–109.6. Tannock I.F., deWit R., Berry W.J. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.et al. N Engl J Med 2004;351:1502–12.Tannock I.F., deWit R., Berry W.J. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.et al. N Engl J Med 2004;351:1502–12.7. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1515–20.Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1515–20.